Latin America, Middle East & Africa Cancer Immunotherapy Market (2018 - 2024)
The Latin America, Middle East and Africa Cancer Immunotherapy Market would witness market growth of 15.5% CAGR during the forecast period (2018 – 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.
Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.
Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd
Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user.
Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cancer Immunotherapy Market, by Technology
1.4.2 LAMEA Cancer Immunotherapy Market, by Application
1.4.3 LAMEA Cancer Immunotherapy Market, by End User
1.4.4 LAMEA Cancer Immunotherapy Market, by Geography
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY
3.1.1 LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country
3.1.2 LAMEA Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
3.1.3 LAMEA Other Technology Cancer Immunotherapy Market by Country
CHAPTER 4. LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION
4.1.1 LAMEA Cancer Immunotherapy Lung Cancer Market by Country
4.1.2 LAMEA Cancer Immunotherapy Breast Cancer Market by Country
4.1.3 LAMEA Cancer Immunotherapy Colorectal Cancer Market by Country
4.1.4 LAMEA Cancer Immunotherapy Melanoma Market by Country
4.1.5 LAMEA Cancer Immunotherapy Prostate Cancer Market by Country
4.1.6 LAMEA Cancer Immunotherapy Head & Neck Cancer Market by Country
4.1.7 LAMEA Other Application Cancer Immunotherapy Market by Country
CHAPTER 5. LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER
5.1.1 LAMEA Hospitals Cancer Immunotherapy Market by Country
5.1.2 LAMEA Clinics Cancer Immunotherapy Market by Country
5.1.3 LAMEA Other End User Cancer Immunotherapy Market by Country
CHAPTER 6. LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
6.1 Brazil Cancer Immunotherapy Market
6.1.1 Brazil Cancer Immunotherapy Market by Technology
6.1.2 Brazil Cancer Immunotherapy Market by Application
6.1.3 Brazil Cancer Immunotherapy Market by End User
6.2 Argentina Cancer Immunotherapy Market
6.2.1 Argentina Cancer Immunotherapy Market by Technology
6.2.2 Argentina Cancer Immunotherapy Market by Application
6.2.3 Argentina Cancer Immunotherapy Market by End User
6.3 UAE Cancer Immunotherapy Market
6.3.1 UAE Cancer Immunotherapy Market by Technology
6.3.2 UAE Cancer Immunotherapy Market by Application
6.3.3 UAE Cancer Immunotherapy Market by End User
6.4 Saudi Arabia Cancer Immunotherapy Market
6.4.1 Saudi Arabia Cancer Immunotherapy Market by Technology
6.4.2 Saudi Arabia Cancer Immunotherapy Market by Application
6.4.3 Saudi Arabia Cancer Immunotherapy Market by End User
6.5 South Africa Cancer Immunotherapy Market
6.5.1 South Africa Cancer Immunotherapy Market by Technology
6.5.2 South Africa Cancer Immunotherapy Market by Application
6.5.3 South Africa Cancer Immunotherapy Market by End User
6.6 Nigeria Cancer Immunotherapy Market
6.6.1 Nigeria Cancer Immunotherapy Market by Technology
6.6.2 Nigeria Cancer Immunotherapy Market by Application
6.6.3 Nigeria Cancer Immunotherapy Market by End User
6.7 Rest of LAMEA Cancer Immunotherapy Market
6.7.1 Rest of LAMEA Cancer Immunotherapy Market by Technology
6.7.2 Rest of LAMEA Cancer Immunotherapy Market by Application
6.7.3 Rest of LAMEA Cancer Immunotherapy Market by End User
CHAPTER 7. COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental & Regional Analysis
7.1.4 Research and Development Expense
7.2 Merck & Company, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional and Segmental Analysis
7.2.4 Research & Development
7.3 Pfizer Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Revenue analysis by Region
7.3.5 Research and Development
7.4 Immunomedics Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Revenue Analysis by Region
7.4.4 Research and Development
7.5 Astrazeneca Plc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental analysis
7.5.4 Research & Development
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Revenue & Segment analysis
7.6.4 Research and Development
7.7 Eli Lilly and Company
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bristol-Myers Squibb Company
7.9.1 Company Overview
7.1 Bayer AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Cancer Immunotherapy Market, by Technology
1.4.2 LAMEA Cancer Immunotherapy Market, by Application
1.4.3 LAMEA Cancer Immunotherapy Market, by End User
1.4.4 LAMEA Cancer Immunotherapy Market, by Geography
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY
3.1.1 LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country
3.1.2 LAMEA Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
3.1.3 LAMEA Other Technology Cancer Immunotherapy Market by Country
CHAPTER 4. LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION
4.1.1 LAMEA Cancer Immunotherapy Lung Cancer Market by Country
4.1.2 LAMEA Cancer Immunotherapy Breast Cancer Market by Country
4.1.3 LAMEA Cancer Immunotherapy Colorectal Cancer Market by Country
4.1.4 LAMEA Cancer Immunotherapy Melanoma Market by Country
4.1.5 LAMEA Cancer Immunotherapy Prostate Cancer Market by Country
4.1.6 LAMEA Cancer Immunotherapy Head & Neck Cancer Market by Country
4.1.7 LAMEA Other Application Cancer Immunotherapy Market by Country
CHAPTER 5. LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER
5.1.1 LAMEA Hospitals Cancer Immunotherapy Market by Country
5.1.2 LAMEA Clinics Cancer Immunotherapy Market by Country
5.1.3 LAMEA Other End User Cancer Immunotherapy Market by Country
CHAPTER 6. LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY
6.1 Brazil Cancer Immunotherapy Market
6.1.1 Brazil Cancer Immunotherapy Market by Technology
6.1.2 Brazil Cancer Immunotherapy Market by Application
6.1.3 Brazil Cancer Immunotherapy Market by End User
6.2 Argentina Cancer Immunotherapy Market
6.2.1 Argentina Cancer Immunotherapy Market by Technology
6.2.2 Argentina Cancer Immunotherapy Market by Application
6.2.3 Argentina Cancer Immunotherapy Market by End User
6.3 UAE Cancer Immunotherapy Market
6.3.1 UAE Cancer Immunotherapy Market by Technology
6.3.2 UAE Cancer Immunotherapy Market by Application
6.3.3 UAE Cancer Immunotherapy Market by End User
6.4 Saudi Arabia Cancer Immunotherapy Market
6.4.1 Saudi Arabia Cancer Immunotherapy Market by Technology
6.4.2 Saudi Arabia Cancer Immunotherapy Market by Application
6.4.3 Saudi Arabia Cancer Immunotherapy Market by End User
6.5 South Africa Cancer Immunotherapy Market
6.5.1 South Africa Cancer Immunotherapy Market by Technology
6.5.2 South Africa Cancer Immunotherapy Market by Application
6.5.3 South Africa Cancer Immunotherapy Market by End User
6.6 Nigeria Cancer Immunotherapy Market
6.6.1 Nigeria Cancer Immunotherapy Market by Technology
6.6.2 Nigeria Cancer Immunotherapy Market by Application
6.6.3 Nigeria Cancer Immunotherapy Market by End User
6.7 Rest of LAMEA Cancer Immunotherapy Market
6.7.1 Rest of LAMEA Cancer Immunotherapy Market by Technology
6.7.2 Rest of LAMEA Cancer Immunotherapy Market by Application
6.7.3 Rest of LAMEA Cancer Immunotherapy Market by End User
CHAPTER 7. COMPANY PROFILES
7.1 Amgen Inc.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental & Regional Analysis
7.1.4 Research and Development Expense
7.2 Merck & Company, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional and Segmental Analysis
7.2.4 Research & Development
7.3 Pfizer Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental &Regional Analysis
7.3.4 Revenue analysis by Region
7.3.5 Research and Development
7.4 Immunomedics Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Revenue Analysis by Region
7.4.4 Research and Development
7.5 Astrazeneca Plc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental analysis
7.5.4 Research & Development
7.6 F. Hoffmann-La Roche Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Revenue & Segment analysis
7.6.4 Research and Development
7.7 Eli Lilly and Company
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Novartis AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Bristol-Myers Squibb Company
7.9.1 Company Overview
7.1 Bayer AG
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
LIST OF TABLES
TABLE 1 LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 2 LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 3 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 4 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 5 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 6 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 7 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 8 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 9 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 10 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 11 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 12 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 13 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 14 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 15 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 16 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 17 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 18 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 19 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 20 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 21 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 22 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 23 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 24 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 25 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 26 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 27 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 28 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 29 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 30 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 31 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 32 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 33 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 34 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 35 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 36 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 37 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 38 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 39 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 40 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 41 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 42 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 43 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 44 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 45 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 46 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 47 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 48 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 49 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 50 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 51 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 52 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 53 UAE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 54 UAE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 55 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 56 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 57 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 58 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 59 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 60 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 61 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 62 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 63 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 64 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 65 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 66 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 67 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 68 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 69 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 70 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 71 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 72 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 73 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 74 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 75 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 76 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 77 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 78 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 79 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 80 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 81 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 82 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 83 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 84 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 85 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 86 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 87 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 88 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 89 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 90 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 91 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 92 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 93 KEY INFORMATION-AMGEN INC.
TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.
TABLE 95 KEY INFORMATION- PFIZER INC.
TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.
TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.
TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
TABLE 99 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 100 KEY INFORMATION – NOVARTIS AG
TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
TABLE 102 KEY INFORMATION – BAYER AG
TABLE 1 LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 2 LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 3 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 4 LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 5 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 6 LAMEA MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 7 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 8 LAMEA CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 9 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 10 LAMEA OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 11 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 12 LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 13 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 14 LAMEA CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 15 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 16 LAMEA CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 17 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 18 LAMEA CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 19 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 20 LAMEA CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 21 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 22 LAMEA CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 23 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 24 LAMEA CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 25 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 26 LAMEA OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 27 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 28 LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 29 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 30 LAMEA HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 31 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 32 LAMEA CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 33 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 34 LAMEA OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 35 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
TABLE 36 LAMEA CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
TABLE 37 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 38 BRAZIL CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 39 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 40 BRAZIL CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 41 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 42 BRAZIL CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 43 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 44 BRAZIL CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 45 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 46 ARGENTINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 47 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 48 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 49 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 50 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 51 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 52 ARGENTINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 53 UAE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 54 UAE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 55 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 56 UAE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 57 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 58 UAE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 59 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 60 UAE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 61 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 62 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 63 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 64 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 65 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 66 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 67 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 68 SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 69 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 70 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 71 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 72 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 73 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 74 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 75 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 76 SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 77 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 78 NIGERIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 79 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 80 NIGERIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 81 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 82 NIGERIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 83 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 84 NIGERIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 85 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
TABLE 86 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
TABLE 87 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
TABLE 88 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
TABLE 89 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
TABLE 90 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
TABLE 91 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
TABLE 92 REST OF LAMEA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
TABLE 93 KEY INFORMATION-AMGEN INC.
TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.
TABLE 95 KEY INFORMATION- PFIZER INC.
TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.
TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.
TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
TABLE 99 KEY INFORMATION – ELI LILLY AND COMPANY
TABLE 100 KEY INFORMATION – NOVARTIS AG
TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
TABLE 102 KEY INFORMATION – BAYER AG
